TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- JUICEWORKS is pleased to announce the expansion of their Safe Entry program with the institution of their first distributor, SBL Technologies Inc (SBL).
Veterans in risk mitigation, SBL has a long-standing reputation for being at the forefront of innovation in workplace safety, particularly for heavy industrial users. Their territory will include North America and the Caribbean. With a strong presence in Canada and the US and a partnership with Sparta Health, SBL is aggressively positioned to permeate the industry vertical with this new offering.
Safe Entry Stations are powered by a proprietary artificial intelligence (AI) algorithm developed by Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF). The clinically-based AI was designed by data scientists and clinicians to identify multiple symptoms of infectious disease, displaying the result in the form of a red or green light.
The technology can also be configured to screen for impairment by THC and alcohol. All screening is entirely autonomous and designed to protect the privacy of the end-user. Completely unique to other solutions on the market, the AI is currently patent pending in North America.
"SBL is an ideal partner to bring this technology to market. They have a unique perspective on the space, having been immersed in it for many years, and appreciate the value of the solution as a long-term risk mitigation tool," commented Jonathan Auger, President & Founder of JUICEWORKS.
Rich Robillard, Managing Director of SBL Testing Technologies, said, "SAFE ENTRY is an incredible screening technology for short and long-term pandemic response/business continuity strategies. The ability to objectively screen for infectious disease symptoms non-invasively and in seconds presents an entirely new first layer of risk mitigation. Albeit responding to the current COVID-19 pandemic and further potential waves or variants, or planning for future infectious diseases that could impact business continuity, SAFE ENTRY is a critical risk mitigation tool."
"The market positioning of SBL in workplace health safety and testing technologies provides us with an ideal partner to scale SAFE ENTRY both for infectious disease screening along with impairment screening all over North America and the Caribbean. Furthermore, the executive team at SBL has a clear vision and action plan for SAFE ENTRY which aligns with the long term vision of Predictmedix," commented Dr. Rahul Kushwah, COO of Predictmedix.
About JUICEWORKS
Founded in 1995 by Jonathan Auger, JUICEWORKS Exhibits began as a one-person team, servicing the exhibit marketing industry. Jon quickly earned the respect of clients and industry peers. This ultimately resulted in a substantial client increase and agency partners throughout North America. Today, with 2 North American locations (Toronto, Las Vegas), JUICEWORKS continues to deliver award-winning projects. Their exponential growth is evident in being recognized by Growth 500 as one of Canada's fastest-growing companies three years running and Lenovo's small business of the year award for 2019. JUICEWORKS is acknowledged by clients globally as the go-to supplier for innovative design, quality craftsmanship and production. Their offerings include commercial space design and production, pop-up shops, custom exhibit/event fabrication, experiential marketing, mobile marketing initiatives, museums and general contracting for events. To find out more, visit getsafeentry.com or juiceworks.ca
Source: JUICEWORKS EXHIBITS
About SBL Testing Technologies
SBL integrates innovative safety & testing technologies into complex workplaces, aligning to corporate risk profiles, HSE programs and operational processes. SBL works with businesses, government agencies, and organizations in all industrial sectors, leveraging technology to reduce risk and enhance policy effectiveness.
SBL's team has successfully provided risk management, safety solutions & workplace testing technologies for decades. Pandemic Response / Business Continuity solutions are led by a team who collectively have 80+ years of delivering fully integrated solutions to government agencies & Fortune 500 companies worldwide.
Source: SBL
About Predictmedix Inc.
Predictmedix Inc. is an artificial intelligence ("AI") company developing disruptive tools for impairment testing and healthcare. It is intended that the Company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.
The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.
Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease. To find out more visit us at www.predictmedix.com
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time."
Source: PREDICTMEDIX, INC
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3fa01a1f-1a87-4f40-af9d-ebecc5613c40
A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/0e3c7919-7942-49eb-b3b8-b7933eb5be58